In 2013, Mayo Clinic instituted an inflammatory bowel disease (IBD) serum biobank involving Mayo campuses in Arizona, Florida and Minnesota and the Mayo Clinic Health System. The goal was to use serologic samples from patients with diagnosed ulcerative colitis (UC) or Crohn's disease (CD) to advance biomarker research that might one day improve diagnosis, prognosis and treatment of IBD. A year after its inception, a serum biobank that unites research across Mayo Clinic is helping identify new serologic biomarkers in patients with Crohn's disease and advancing other IBD research.
Read more about the biobank here.
For more information on IBD, visit mayoclinic.org/ibd.